1357 related articles for article (PubMed ID: 15754326)
21. Predictive value of lymph node and tumor matrix metalloproteinase expression in the analysis of metastatic periampullary tumors.
McKenna GJ; Meneghetti A; Chen YL; Mui AL; Ong C; Scudamore CH; McMaster WR; Owen DA; Chung SW
J Surg Oncol; 2005 Jun; 90(4):239-46. PubMed ID: 15906368
[TBL] [Abstract][Full Text] [Related]
22. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
23. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases.
Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Kamide Y; Ishizuka T; Kanai Y; Nakajima T; Mori M
Ann Surg Oncol; 2009 Dec; 16(12):3473-81. PubMed ID: 19777189
[TBL] [Abstract][Full Text] [Related]
24. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Ang-2 mRNA in non-small cell lung cancer: association with angiogenesis and poor prognosis.
Takanami I
Oncol Rep; 2004 Oct; 12(4):849-53. PubMed ID: 15375511
[TBL] [Abstract][Full Text] [Related]
26. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.
Li L; Mei TH; Zhou XD; Zhang XG
Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419
[TBL] [Abstract][Full Text] [Related]
27. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
[TBL] [Abstract][Full Text] [Related]
28. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival.
Zheng S; Chang Y; Hodges KB; Sun Y; Ma X; Xue Y; Williamson SR; Lopez-Beltran A; Montironi R; Cheng L
Anticancer Res; 2010 Mar; 30(3):713-8. PubMed ID: 20392988
[TBL] [Abstract][Full Text] [Related]
29. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer.
Thomas P; Khokha R; Shepherd FA; Feld R; Tsao MS
J Pathol; 2000 Feb; 190(2):150-6. PubMed ID: 10657012
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
32. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma.
de Vicente JC; Fresno MF; Villalain L; Vega JA; López Arranz JS
Oral Oncol; 2005 Jul; 41(6):568-79. PubMed ID: 15925538
[TBL] [Abstract][Full Text] [Related]
33. [Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix].
Zhou CY; Yao JF; Chen XD
Ai Zheng; 2002 Jul; 21(7):735-9. PubMed ID: 12479097
[TBL] [Abstract][Full Text] [Related]
34. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer.
Suemitsu R; Yoshino I; Tomiyasu M; Fukuyama S; Okamoto T; Maehara Y
Surg Today; 2004; 34(11):896-901. PubMed ID: 15526122
[TBL] [Abstract][Full Text] [Related]
35. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
[TBL] [Abstract][Full Text] [Related]
36. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
Pérez P; Kwon YJ; Alliende C; Leyton L; Aguilera S; Molina C; Labra C; Julio M; Leyton C; González MJ
Arthritis Rheum; 2005 Sep; 52(9):2751-60. PubMed ID: 16142742
[TBL] [Abstract][Full Text] [Related]
37. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Hsu CP; Shen GH; Ko JL
Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
[TBL] [Abstract][Full Text] [Related]
39. TIMP1 and adverse prognosis in non-small cell lung cancer.
Fong KM; Kida Y; Zimmerman PV; Smith PJ
Clin Cancer Res; 1996 Aug; 2(8):1369-72. PubMed ID: 9816309
[TBL] [Abstract][Full Text] [Related]
40. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
